Improved inhalation therapies of brittle powders

Simple item page
dc.contributor.advisorWilliams, Robert O., 1956-
dc.creatorCarvalho, Simone Raffaen
dc.date.accessioned2015-03-03T19:15:45Zen
dc.date.accessioned2018-01-22T22:27:33Z
dc.date.available2018-01-22T22:27:33Z
dc.date.issued2013-12en
dc.date.submittedDecember 2013en
dc.date.updated2015-03-03T19:15:45Zen
dc.descriptiontexten
dc.description.abstractAdvancements in pulmonary drug delivery technologies have improved the use of dry powder inhalation therapy to treat respiratory and systemic diseases. Despite remarkable improvements in the development of dry powder inhaler devices (DPIs) and formulations in the last few years, an optimized DPI system has yet to be developed. In this work, we hypothesize that Thin Film Freezing (TFF) is a suitable technology to improve inhalation therapies to treat lung and systemic malignancies due to its ability to produce brittle powder with optimal aerodynamic properties. Also, we developed a performance verification test (PVT) for the Next Generation Cascade Impactor (NGI), which is one of the most important in vitro characterization methods to test inhalation. In the first study, we used TFF technology to produce amorphous and brittle particles of rapamycin, and compared the in vivo behavior by the pharmacokinetic profiles, to its crystalline counterpart when delivered to the lungs of rats via inhalation. It was found that TFF rapamycin presented higher in vivo systemic bioavailability than the crystalline formulation. Subsequently, we investigated the use of TFF technology to produce triple fixed dose therapy using formoterol fumarate, tiotropium bromide and budesonide as therapeutic drugs. We investigated applications of this technology to powder properties and in vitro aerosol performance with respect to single and combination therapy. As a result, the brittle TFF powders presented superior properties than the physical mixture of micronized crystalline powders, such as excellent particle distribution homogeneity after in vitro aerosolization. Lastly, we developed a PVT for the NGI that may be applicable to other cascade impactors, by investigating the use of a standardized pressurized metered dose inhaler (pMDI) with the NGI. Two standardized formulations were developed. Formulations were analyzed for repeatability and robustness, and found not to demonstrate significant differences in plate deposition using a single NGI apparatus. Variable conditions were introduced to the NGI to mimic operator and equipment failure. Introduction of the variable conditions to the NGI was found to significantly adjust the deposition patterns of the standardized formulations, suggesting that their use as a PVT could be useful and that further investigation is warranted.en
dc.description.departmentPharmaceutical Sciencesen
dc.format.mimetypeapplication/pdfen
dc.identifier.urihttp://hdl.handle.net/2152/28736en
dc.subjectPulmonary deliveryen
dc.subjectInhalationen
dc.subjectParticle engineeringen
dc.subjectDry powder formulationen
dc.subjectRapamycinen
dc.subjectBudesonideen
dc.subjectTriotropium bromideen
dc.subjectFormoterol fumarateen
dc.subjectPharmacokineticsen
dc.subjectFixed-dose combinationen
dc.subjectTriple combo formulationen
dc.subjectPerformance verification testen
dc.subjectCascade impactoren
dc.subjectCalibrationen
dc.subjectDry powder inhaleren
dc.subjectThin film freezingen
dc.subjectLyophilizationen
dc.subjectBrittle powderen
dc.titleImproved inhalation therapies of brittle powdersen
dc.typeThesisen

Files

Collections

University of Texas at Austin